WEBULL
News
RLAY
8.56
-1.04%
-0.09
Interesting RLAY Call Options For February 2026
NASDAQ · 4d ago
Weekly Report: what happened at RLAY last week (1215-1219)?
Weekly Report · 4d ago
CANCER DRUG DEVELOPERS SECURE REGULATORY CLARITY AS FDA RESHAPES APPROVAL STANDARDS
Reuters · 12/16 17:18
Weekly Report: what happened at RLAY last week (1208-1212)?
Weekly Report · 12/15 10:00
Relay Therapeutics Reports 'Robust Activity' For Precision Breast Cancer Drug
Benzinga · 12/12 18:30
Relay Therapeutics Price Target Raised to $13.00/Share From $6.00 by Wells Fargo
Dow Jones · 12/12 16:41
Relay Therapeutics Raised to Overweight From Equal-Weight by Wells Fargo
Dow Jones · 12/12 16:41
Wells Fargo Upgrades Relay Therapeutics to Overweight, Raises Price Target to $13
Benzinga · 12/12 16:31
Relay Therapeutics announces analysis of data for zovegalisib
TipRanks · 12/12 12:05
Relay Therapeutics Presents Subset Analysis Of Interim Phase 3 Data For Zovegalisib At SABCS 2025
Benzinga · 12/12 12:05
Relay Therapeutics Reports Promising Zovegalisib Results in Phase 3 Breast Cancer Trial
Reuters · 12/12 12:00
Positive Report for Relay Therapeutics (RLAY) from Wells Fargo
TipRanks · 12/12 10:35
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
Barchart · 12/12 06:00
Weekly Report: what happened at RLAY last week (1201-1205)?
Weekly Report · 12/08 09:58
Weekly Report: what happened at RLAY last week (1124-1128)?
Weekly Report · 12/01 09:55
Alibaba, Oscar Health, Ondas Holdings, Lumentum, Tesla And Other Big Stocks Moving Higher On Monday
Benzinga · 11/24 16:06
Weekly Report: what happened at RLAY last week (1117-1121)?
Weekly Report · 11/24 09:59
Barclays Sticks to Its Buy Rating for Relay Therapeutics (RLAY)
TipRanks · 11/24 08:46
Commit To Buy Relay Therapeutics At $5, Earn 22.4% Annualized Using Options
NASDAQ · 11/18 16:36
Weekly Report: what happened at RLAY last week (1110-1114)?
Weekly Report · 11/17 09:59
More
Webull provides a variety of real-time RLAY stock news. You can receive the latest news about Relay Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RLAY
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.